Lys338
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.8.0
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys338  -  Myc (mouse)

Site Information
RKDYPAAkRAKLDsG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 458888

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 , 3 ) , mass spectrometry ( 1 , 3 ) , modification-specific antibody ( 2 ) , mutation of modification site ( 3 ) , peptide sequencing ( 3 ) , western blotting ( 1 , 2 , 3 )
Disease tissue studied:
breast cancer ( 1 ) , lung cancer ( 3 ) , non-small cell lung cancer ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
siRNA ( 2 )

Downstream Regulation
Effects of modification on Myc:
activity, induced ( 2 ) , protein stabilization ( 1 , 3 )
Effects of modification on biological processes:
cell differentiation, induced ( 2 ) , cell growth, induced ( 2 ) , transcription, induced ( 3 )

References 

1

Hurd M, et al. (2023) MYC acetylated lysine residues drive oncogenic cell transformation and regulate select genetic programs for cell adhesion-independent growth and survival. Genes Dev 37, 865-882
37852796   Curated Info

2

Abdesselem H, et al. (2016) SIRT1 Limits Adipocyte Hyperplasia through c-Myc Inhibition. J Biol Chem 291, 2119-35
26655722   Curated Info

3

Patel JH, et al. (2004) The c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60. Mol Cell Biol 24, 10826-34
15572685   Curated Info